FindTrial
Sign In

Ultrasound Diagnosis of Endometrial Hyperplasia After Tamoxifen Therapy in Breast Cancer Women

Ultrasound Diagnosis of Endometrial Hyperplasia After Tamoxifen Therapy in Breast Cancer Women

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015719
Enrollment
Unknown
Registered
2018-04-16
Start date
2018-05-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial disease after endocrinotherapy in breast cancer women

Interventions

two:Hysteroscopic surgery

Sponsors

Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 80 Years

Inclusion criteria

Inclusion criteria: Oral tamoxifen (or other endocrine medicine) for patients with breast cancer for more than 6 months

Exclusion criteria

Exclusion criteria: Liver and renal disfunction and other serious insufficiency; hematological pathological changes; allergies; In combination with other malignancies except breast cancer and endometrial cancer; Before the oral administration of tamoxifen, abnormal endometrial hyperplasia or even endometrial cancer has occurred.

Design outcomes

Primary

MeasureTime frame
endometrial thickness by the B Ultrasound ;—

Countries

China

Contacts

Public ContactHe Yue

Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University

yueyue870610@126.com+86 13681565788

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026